AU580117B2 - Analgesic compositions - Google Patents

Analgesic compositions

Info

Publication number
AU580117B2
AU580117B2 AU50585/85A AU5058585A AU580117B2 AU 580117 B2 AU580117 B2 AU 580117B2 AU 50585/85 A AU50585/85 A AU 50585/85A AU 5058585 A AU5058585 A AU 5058585A AU 580117 B2 AU580117 B2 AU 580117B2
Authority
AU
Australia
Prior art keywords
analgesic compositions
analgesic
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU50585/85A
Other languages
English (en)
Other versions
AU5058585A (en
Inventor
John William Lewis
John Gareth Lloyd-Jones
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Reckitt Benckiser Healthcare UK Ltd
Original Assignee
Reckitt and Colman Products Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reckitt and Colman Products Ltd filed Critical Reckitt and Colman Products Ltd
Publication of AU5058585A publication Critical patent/AU5058585A/en
Application granted granted Critical
Publication of AU580117B2 publication Critical patent/AU580117B2/en
Assigned to RECKITT & COLMAN PRODUCTS LIMITED reassignment RECKITT & COLMAN PRODUCTS LIMITED Assignment by Patentee under S 187, Reg 19.1 Assignors: RECKITT & COLMAN PRODUCTS LIMITED
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU50585/85A 1984-11-30 1985-11-29 Analgesic compositions Ceased AU580117B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB848430346A GB8430346D0 (en) 1984-11-30 1984-11-30 Analgesic compositions
GB8430346 1984-11-30

Publications (2)

Publication Number Publication Date
AU5058585A AU5058585A (en) 1986-06-05
AU580117B2 true AU580117B2 (en) 1989-01-05

Family

ID=10570540

Family Applications (1)

Application Number Title Priority Date Filing Date
AU50585/85A Ceased AU580117B2 (en) 1984-11-30 1985-11-29 Analgesic compositions

Country Status (12)

Country Link
US (1) US4661492A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EP (1) EP0185472B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPS61191613A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU580117B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA1255595A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (1) DE3575070D1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK160914C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (2) GB8430346D0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GR (1) GR852883B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ214223A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT81583B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA858995B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU621952B2 (en) * 1988-11-01 1992-03-26 Alza Corporation Dosage form having reduced abuse potential

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2213058B (en) * 1987-12-03 1991-07-17 Reckitt & Colmann Prod Ltd Compositions comprising buprenorphine and naltrexone for treatment of opiate addicts
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5272149A (en) * 1992-05-05 1993-12-21 Stalling Reginald W Symptom controlled receptor substitution for addiction withdrawl
US5512578A (en) * 1992-09-21 1996-04-30 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists
US6096756A (en) 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
DE19652188C2 (de) * 1996-12-16 2002-02-14 Lohmann Therapie Syst Lts Flache Arzneizubereitung zur Applikation und Freisetzung von Buprenorphin oder einer pharmakologisch vergleichbaren Substanz in der Mundhöhle und Verfahren zu ihrer Herstellung
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US7220737B1 (en) 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
WO1999011250A2 (en) * 1997-09-04 1999-03-11 Novoneuron, Inc. Noribogaine in the treatment of pain and drug addiction
US6228863B1 (en) * 1997-12-22 2001-05-08 Euro-Celtique S.A. Method of preventing abuse of opioid dosage forms
ES2415876T3 (es) 1997-12-22 2013-07-29 Euro-Celtique S.A. Forma de dosificación farmacéutica oral que comprende una combinación de un agonista de opiáceos y un antagonista de opiáceos
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
EP0984276A4 (en) * 1998-02-16 2003-08-27 Inst Physical & Chem Res CAPILLARY CASSETTE AND METHOD FOR THE PRODUCTION THEREOF
US6007841A (en) * 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US6849263B2 (en) * 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
CN1248689C (zh) * 1999-08-27 2006-04-05 南方研究所 可注射的美沙酮、丁丙诺啡微粒组合物及其用途
RU2147880C1 (ru) * 1999-11-10 2000-04-27 Мамренко Валерий Русланович Лекарственное средство для лечения пациентов с хроническим алкоголизмом и способ их лечения
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
ATE431145T1 (de) * 2000-02-08 2009-05-15 Euro Celtique Sa Missbrauchssichere orale opioid-agonist zubereitungen
EP1387673B1 (en) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Abuse-resistant controlled-release opioid dosage form
US20030035839A1 (en) * 2001-05-15 2003-02-20 Peirce Management, Llc Pharmaceutical composition for both intraoral and oral administration
US20030022909A1 (en) * 2001-06-05 2003-01-30 University Of Chicago Use of methylnaltrexone to treat immune suppression
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
CN1268338C (zh) * 2001-07-06 2006-08-09 恩德制药公司 用作止痛剂的6－羟基羟吗啡酮的口服给药
US20030129234A1 (en) * 2001-07-06 2003-07-10 Penwest Pharmaceuticals Company Methods of making sustained release formulations of oxymorphone
PT1416842E (pt) * 2001-07-18 2009-03-31 Euro Celtique Sa Composições farmacêuticas de oxicodona e naloxona
RU2004106619A (ru) 2001-08-06 2005-07-10 Эро-Селтик С.А. (Lu) Композиции опиоидного агониста, содержащие высвобождаемый и изолированный антагонист
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
US20030091635A1 (en) * 2001-09-26 2003-05-15 Baichwal Anand R. Opioid formulations having reduced potential for abuse
US6863901B2 (en) * 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
US6827946B2 (en) * 2001-12-05 2004-12-07 Collegium Pharmaceutical, Inc. Compositions containing both sedative and non-sedative antihistamines
DK2425821T5 (en) 2002-04-05 2018-02-12 Mundipharma As Pharmaceutical preparation containing oxycodone and naloxone
EP1509182A4 (en) * 2002-05-31 2009-12-30 Titan Pharmaceuticals Inc IMPLANTABLE POLYMERS DEVICE FOR THE DELAYED RELEASE OF BUPRENORPHINE
WO2004026283A1 (en) * 2002-09-20 2004-04-01 Alpharma, Inc. Sequestering subunit and related compositions and metohds
WO2004082620A2 (en) * 2003-03-13 2004-09-30 Controlled Chemicals, Inc. Oxycodone conjugates with lower the abuse potential and extended duration of action
ZA200507877B (en) * 2003-03-31 2007-01-31 Titan Pharmaceuticals Inc Implantable polymeric device for sustained release of dopamine agonist
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) * 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP3326617A1 (en) 2004-06-12 2018-05-30 Collegium Pharmaceutical, Inc. Abuse-deterrent drug formulations
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US7568409B2 (en) * 2005-03-30 2009-08-04 Federal-Mogul World Wide, Inc Hybrid orbiting spindle for shaping non-circular holes
FR2898056B1 (fr) 2006-03-01 2012-01-20 Ethypharm Sa Comprimes resistant a l'ecrasement destines a eviter le detournement illicite
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
MX2008016372A (es) 2006-06-19 2009-05-28 Alpharma Inc Composiciones farmaceuticas.
EP1897543A1 (en) 2006-08-30 2008-03-12 Euro-Celtique S.A. Buprenorphine- wafer for drug substitution therapy
ES2439581T3 (es) 2006-12-04 2014-01-23 Orexo Ab Nueva composición farmacéutica no susceptible de abuso que comprende opioides
US20080199407A1 (en) 2007-02-15 2008-08-21 Slater Kenneth C Drug Detoxification Protocol Using Microdosing
US20080207593A1 (en) * 2007-02-28 2008-08-28 Collegium Pharmaceutical, Inc. Antihistamine Combination
GB2447014A (en) 2007-03-01 2008-09-03 Reckitt Benckiser Healthcare Analgesic composition comprising a specific ratio of buprenorphine and naltrexone
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
WO2009088673A2 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
US20110177133A1 (en) * 2008-07-07 2011-07-21 Michael Hopp Use of opioid antagonists for treating urinary retention
AU2010223323B2 (en) 2009-03-10 2013-07-04 Euro-Celtique S.A. Immediate release pharmaceutical compositions comprising oxycodone and naloxone
US8475832B2 (en) 2009-08-07 2013-07-02 Rb Pharmaceuticals Limited Sublingual and buccal film compositions
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
MX2013000733A (es) 2010-07-23 2013-05-30 Demerx Inc Composiciones de noribogaina.
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
PL2915525T3 (pl) 2011-09-19 2022-01-17 Orexo Ab Tabletki podjęzykowe niepodatne na nadużywanie zawierające buprenorfinę i nalokson
JP2015500833A (ja) 2011-12-09 2015-01-08 デメレックス， インコーポレイテッド ノルイボガインのリン酸エステル
US9211293B2 (en) * 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
US8877921B2 (en) 2012-01-25 2014-11-04 Demerx, Inc. Synthetic voacangine
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
EP2934541A4 (en) 2012-12-20 2016-08-03 Demerx Inc NORIBOGAINE SUBSTITUTE
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
US10071089B2 (en) 2013-07-23 2018-09-11 Euro-Celtique S.A. Combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
WO2015195673A2 (en) 2014-06-18 2015-12-23 Demerx, Inc. Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
US20170065580A1 (en) * 2015-09-09 2017-03-09 Biodelivery Sciences International, Inc. Methods of safely transitioning a subject to buprenorphine
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
CN111479592B (zh) 2017-11-15 2023-05-26 加利福尼亚大学董事会 阿片样物质使用障碍、阿片样物质戒断症状和慢性疼痛的治疗

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
AU3632984A (en) * 1983-12-06 1985-06-13 Reckitt Benckiser Healthcare (Uk) Limited Buprenorphine and naloxone composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4457933A (en) * 1980-01-24 1984-07-03 Bristol-Myers Company Prevention of analgesic abuse
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
AU3632984A (en) * 1983-12-06 1985-06-13 Reckitt Benckiser Healthcare (Uk) Limited Buprenorphine and naloxone composition

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU621952B2 (en) * 1988-11-01 1992-03-26 Alza Corporation Dosage form having reduced abuse potential

Also Published As

Publication number Publication date
EP0185472A1 (en) 1986-06-25
EP0185472B1 (en) 1990-01-03
DE3575070D1 (de) 1990-02-08
ZA858995B (en) 1986-07-30
GB8430346D0 (en) 1985-01-09
DK160914B (da) 1991-05-06
NZ214223A (en) 1989-02-24
AU5058585A (en) 1986-06-05
GB2167663B (en) 1988-10-12
GR852883B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1986-04-01
US4661492A (en) 1987-04-28
JPS61191613A (ja) 1986-08-26
GB2167663A (en) 1986-06-04
PT81583B (pt) 1988-01-22
DK555185A (da) 1986-05-31
PT81583A (en) 1985-12-01
JPH0586764B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1993-12-14
GB8528784D0 (en) 1985-12-24
DK160914C (da) 1991-10-21
DK555185D0 (da) 1985-11-29
CA1255595A (en) 1989-06-13

Similar Documents

Publication Publication Date Title
AU580117B2 (en) Analgesic compositions
AU568550B2 (en) Analgesic compositions
GB2152815B (en) Analgesic compositions
AU590305B2 (en) Photopolymerizable composition
AU591161B2 (en) Fly-attractive composition
AU549070B2 (en) Nalbuphine-narcotic analgesic composition
AU4454389A (en) Pharmaceutical composition
AU584681B2 (en) Analgesic composition
AU580322B2 (en) Shampoo compositions
AU579433B2 (en) Polycarbonate compositions
AU582369B2 (en) Aminophenol compounds
AU584678B2 (en) Analgesic composition
AU590750B2 (en) Compositions
AU588370B2 (en) Desealing compositions
AU5245586A (en) Compositions
AU623694B2 (en) Metoclopramide compositions
AU3766085A (en) Fungicidal composition
AU4523185A (en) Cementitious compositions
AU4430685A (en) Topical compositions
AU570478B2 (en) Fungicidal compositions
AU585411B2 (en) Aminomethylenephosphonate compositions
AU580577B2 (en) Compositions
AU578657B2 (en) Pharmaceutical compositions
AU581201B2 (en) Fungicidal compositions
AU578273B2 (en) Trahsdermal bopindolol compositions

Legal Events

Date Code Title Description
MK14 Patent ceased section 143(a) (annual fees not paid) or expired